

## Index

### **a**

acylation 93  
 adenosine deaminase inhibitor 83, 84  
 $\alpha_2$ -adrenaleptor-sparing PDE4 inhibitor 59  
 alkylation 16, 93  
 aminoquinazoline 160  
 – chemical synthesis 161  
 amrinone 1, 3  
 antiapoptotic effect, on beta cells 105  
 antinociceptive activity 95  
 apremilast 47, 49, 59  
 $\beta$ -arrestin 30  
 atropisomerism 93  
 avanafil 2, 5, 11, 12, 25

### **b**

benzodiazepine inhibitors 95, 96  
 benzotriazine derivatives, and synthetic approach 87, 88  
 benzylamino pyridopyrimidine PDE2A inhibitors 97

### **c**

calcium/calmodulin (CaM) binding sites 155  
 cAMP response element-binding protein (CREB) 65, 70  
 catalytic domains 50  
 – amino acid variations 199  
 – conserved catalytic domain 46  
 – constructs 35, 38  
 – C-terminus/N-terminus, role in 33, 34, 36, 37  
 – dimer of the PDE9 catalytic domain 106  
 – domains UCR1 and UCR2 30  
 – LmjPDEB1, P-pocket extends from 202  
 – metal binding region 193  
 – MP10/PF-2545920 bound in catalytic domain of PDE10A 74  
 – of PDE1-10 7

– of PDE5 15  
 – PDE10A catalytic domain bound with AMP 68  
 – of PDE4B 7, 31  
 – structure of PDE9 catalytic domain 107  
 – UCR2–catalytic domain interaction 39  
 cell death 1, 194, 201, 203  
 central nervous system (CNS) 24, 59, 65, 79, 83, 105, 117, 161  
 – analysis desirability of PDE9A inhibitors 135  
 – PDE7 Inhibitors for CNS-related disorders 173–178  
 Chagas disease 7, 191, 195  
 – current therapeutics 195  
 – first stage of infection 195  
 – phosphodiesterases 195  
 – Romana's sign 195  
 – symptoms 195  
 – TcrPDEA1 195  
 – TcrPDEB family 195, 196  
 – TcrPDEC 196  
 – inhibitors 196, 197  
 chronic obstructive pulmonary disease (COPD) 1, 3, 11, 29, 48, 58, 60, 170, 179  
 cilomilast 47, 48, 49, 53, 56, 60  
 CNS multiparametric optimization (MPO) tool 135  
 crystal structures  
 – for LmjPDEB1 198  
 – PDE domain 7  
 – PDE2, regulatory domains 31  
 – PDE2A inhibitors 97  
 – PDE3 71  
 – PDE4  
 – deCODE, elucidation 49–53, 60  
 – regulatory domains 33  
 – PDE4B 35  
 – 3G45 36  
 – regulatory domains, 35

- PDE4D 35
- PMNPQ bound 39
- regulatory domains, 35
- PDE5
  - designed quinolone 20
  - use at HTS stage 19, 20
- PDE7A1 catalytic domain 174
- PDE9A
  - in complex 105, 108
  - inhibitors 119, 123–125, 127, 128, 130–134
- PDE10 14
- PDE10A
  - hybrid quinazoline/PF-2545920 series 73, 75, 77
  - Pfizer 489 69
  - PQ-10, with PDE3 residues 71
- cyclic adenosine monophosphate (cAMP) 1, 117, 155, 192
  - binding to catalytic site of PDE10A 70
  - hydrolyzing activity 141
  - specific hydrolases 45
- cyclic guanosine 3′-5′-monophosphate (cGMP) 1, 29, 117, 155, 192
  - regulated processes 9
  - signaling in cognitive processing 117
  - specific phosphodiesterases 105
- cyclic nucleotide phosphodiesterases 1, 29
- cytotoxic T-lymphocytes (CTL) 171

**d**

- design principles 7
- dimethoxy catechol papaverine-type inhibitor
  - class of PDE10A 71
- DISC1 gene 38
- dopamine (D2) neurons 65
- dopamine receptor 177
- dopamine transporter (DAT) activity 128
- drug discovery 9, 45, 191, 205, 206
- drug–drug interactions (DDIs) 72

**e**

- EHNA (erythro-9-(2-hydroxy-3-nonyl)adenine) 83, 84
- ethoxyethyl 22
  - optimized to propoxyethyl to enlarge the selectivity 22
  - of PF-489791 19
  - selection 16
- expressed sequence tags (ESTs) 141

**f**

- first-generation agents 10

**g**

- gene activation 1
- G-protein coupled receptors (GPCRs) 29, 127
- GSK256066, inhaled PDE4 inhibitor 57, 58

**h**

- high-throughput screen (HTS)
  - based on docking models 56
  - fission yeast-based HTS to identify new PDE7 inhibitors 183
  - PDE5, full file high-throughput screening (HTS) campaign 14
  - 4-quinolone HTS hit 20
  - singleton HTS hit CP-189824 bound in PDE5 19
  - and subsequent IC<sub>50</sub> determinations 90
  - triage stage 15
- HTS. *see* high-throughput screen (HTS)
- human African trypanosomiasis (HAT) 200–205
  - analogs of sildenafil and tadalafil with antitrypanosomal activity 205
  - catechol TbrPDEB inhibitor identified from HIT campaign 205
  - chemotherapeutics 200, 201
  - five cAMP-specific PDEs, *T. brucei* 201
  - TbrPDEA 201
    - inhibitors of 201
  - TbrPDEB 201, 202
  - homology model 202
  - hPDE5 inhibitors, SAR study 202
  - protozoan parasite 200
  - stages of disease 200
  - structures of hPDE4 chemotypes 203
  - studies of established inhibitor chemotypes
  - against protozoan PDEs of potential therapeutic relevance 204
- Huntington's disease 7, 65, 79, 117, 156
  - PDE10A inhibitors, therapeutic potential 65
- hydrolysis 66, 67, 83, 119, 120, 155, 192
  - cAMP, by recombinant PDE4A–PDE4D isozymes 54
  - cGMP 196
  - cyclic nucleotides 32
  - by PDEs 2
  - cyclic phosphate ester 120
- hydrophobic clamp 32, 47, 68, 73, 75, 77, 86, 99, 120, 123, 198, 202
- hydrophobic protein 97

**i**

- imidazotriazine inhibitors 98
- 3-isobutyl-1-methylxanthine (IBMX) 105, 107, 109, 110, 112, 113, 119, 141, 145, 146, 157, 195, 198, 199, 202, 204
- isoquinolinium salt 146

**l**

- leishmaniasis 197–200
  - cAMP-specific PDE activity in *Leishmania mexicana* 199
  - current therapeutics 198
  - disease cycle 198
  - *Leishmania donovani* encod PDEs 199, 200
  - – inhibitors 200
  - *Leishmania major* (LmjPDEs) 198, 199
  - – LmjPDEA 198, 199
  - – LmjPDEB1 198, 199
  - protozoan parasite 198
- ligand docking calculations 100
- ligand–enzyme interactions 95
- lipophilic effects 20, 22, 95

**m**

- malaria 191
  - asymptomatic exoerythrocytic stage 192
  - drug therapies 192
  - erythrocytic cycle 192
  - infection spreads via 192
  - as infectious disease 192
  - parasite's life cycle 192, 193
  - PfPDE inhibition studies 193, 194
  - *Plasmodium* genus (protozoan parasite) 192
  - sporogonic cycle 192
- male erectile dysfunction (MED) 9, 11, 52
  - PDE5 as a mechanism and alternative indications beyond 11
  - sildenafil 1, 2, 9, 10
  - tadalafil 1, 2, 9, 10
  - vardenafil 1, 4, 9–11, 25, 156, 157
- mammalian PDE4 genes 30
  - isoforms 30
  - splice variants of human PDE4B 30
  - splicing 30
  - UCR1 and UCR2, as upstream conserved regions 30, 31
- MED. *see* Male erectile dysfunction (MED)
- 4-methoxy pyridine 22
- 4-(methylamino)phenol 95
- milrinone 1, 3, 195, 204
- mirodenafil (Mvix<sup>®</sup>) 1, 5, 11, 12, 25
- modular synthetic strategies 97–99

- MP-10/PF-2545920 class of inhibitors 72–74
  - design and development 72
  - high throughput screen (HTS) to identify 72
  - inhibition of CYPs 72
  - reagents and conditions 73
  - structure–activity relationship (SAR) development 72
  - synthesis 72
  - treatment of schizophrenia 72

**n**

- N*-acylhydrazones, as selective PDE10 inhibitors 76
- natural killer T (NKT) cells 171
- neuroplasticity 1, 156
- neurotransmission 1, 156
- N*-methyl D-aspartate (NMDA) 118

**o**

- olanzapine derivatives 58, 59
- ortho*-chlorobenzylamine 132
- oxindole 95
  - PDE potency and selectivity 96

**p**

- pan-PDE4 inhibitors 46
- parallel medicinal chemistry (PMC) approaches 94
  - accessing variety of aryl substituents 94
- PDE1 enzymology 155, 156
- PDE genes 29, 31, 179
- PDE inhibitors 1
  - patent landscape 6
  - peak sales of PDE inhibitors 3–5
- PDE1 inhibitors 6, 155, 156
  - clinical trials, treatment of cognitive disorders 7
- imidazo pyrazolopyrimidines
  - – intracellular therapies 159
- isoenzymes 155
- non-selective PDE1 inhibitors 156–158
  - – structures and IC<sub>50</sub> values of 157
- quinazoline inhibitors (*see* quinazoline inhibitors)
- selective inhibitors 158–161
- PDE2 inhibitors 6, 95, 101
  - clinical trials, for treatment of cognitive disorders 7
- crystal structure 7
- PDE2A inhibitors 83
  - – acceleration in cAMP turnover 83
  - – benzodiazepine inhibitors 95, 96

- Biotie Therapies, benzotriazine derivatives and synthetic approach 87, 88
- Biotie Therapies pyridotriazine derivatives 89
- disclosed by Lundbeck 93
- hydroxyethyl substituent, as determinant of potency 97
- imidazotriazine inhibitors 98
- including PDP and BAY 60-7550 84
- inhibition, elicit pharmacological effects 83
- isozyme-selective inhibitor EHNA 84
- ligand docking calculations 100
- from Merck, and synthetic sequence to access 94
- PDE potency and selectivity of IZT derivative 99
- potency and selectivity of BAY 60-7550 85
- proposed binding mode of Merck compound 95
- proposed PDE2A binding mode 87
- purin-6-one compounds 86
- pyrazolodiazepinone inhibitors 97
- pyrazolopyrimidine inhibitors 98, 100
- pyridopyrimidine inhibitors 98
- quinolinone inhibitors 93
- role as a regulatory enzyme in 83
- 1,2,4-triazolo[4,3- $\alpha$ ]quinoxaline compounds 88–92
- triazolophthalazines 86
- PDE3 inhibitors 1, 3, 67, 76, 85, 162, 193, 195, 199, 204
- PDE4 inhibitors
  - associated with inflammatory response 45
  - catalytic domain of PDE4B, useful in design of 32
  - comparison of UCR2 helix and C terminal helix interactions with 37
  - crystal structure of regulatory domains 33–38
  - different classes of 35
  - DISC1 gene, disruption 38
  - for inflammatory disorders 7
  - modes of closing access to catalytic site 37
  - observation of “capped” catalytic site 37
  - pan-PDE4 inhibitors 45
  - PDE4b crystallographic dimer 36
  - PDE4D retain catalytic activity 38
  - PDE4 strategies to avoid gastrointestinal events 49
  - allosteric modulation 49–53
  - B-selective Asahi Kasei inhibitor 56
  - nicotinamides (A) 53
  - olanzapine derivatives 58, 59
  - organization contributions 54–57
    - Asahi Kasei 56
    - GlaxoSmithKline 56, 57
    - Merck-Frosst 54
    - Novartis 54
    - Pfizer 54, 57
  - patents, describing D-selective chemical matter 53
  - PDE4B selective inhibitors 55, 56
  - PDE4D selective compounds 53
  - polypharmacology 58
  - Rolipram analogs 55
  - study of GEBR-7b, in emesis models 55
  - tissue targeting 57, 58
  - regulation of activity 32, 33
  - roflumilast 1, 6, 29, 46–48, 52, 59, 202–204
  - splice variants 46
  - strategies to avoid gastrointestinal events
  - structural features, of catalytic site 31, 32
  - structure of regulatory domain of PDE4B 34
  - tetrahydrobenzothiophene (THBT)-based PDE4B inhibitors 56
  - therapeutic use 29
    - as topical agents for atopic dermatitis 7
    - treatment of cognitive disorders 7
    - treatment of depression and anxiety 7
  - UCR2 interaction, and selectivity 38, 39
- PDE5 inhibitors 1, 2, 6, 9, 11, 13, 21, 23, 24, 156, 194
  - chemotype, reported Post-2010 11, 12
  - patent filings 12
  - clinical development, Phase 2 for renal disease 7
  - clinical utility for 6
  - for male erectile dysfunction (MED) 9
  - mechanism and alternative indications beyond MED 11
    - indications, investigated 11
  - pharmacological selectivity 9
  - second-generation (*see* pyrazolopyrimidines; pyridopyrazinones)
  - tadalafil chemotype, for improved potency 194
- PDE6 inhibitors 6
- PDE7 inhibitors 6
  - dopamine receptor intracellular signaling pathway, regulation 177
  - as dual inhibitors 168, 179, 184
  - topigen 179
  - furan-containing class of PDE7 inhibitors 176
  - historical development 166
  - identifying next-generation inhibitors 181

- emerging chemotypes as novel inhibitors 181, 182
- isoenzymes 165
- PDE7A1 165
- PDE7A2 165
- PDE7B 165, 166
- nonselective/selective lead matter, early examples 166–168
- novel methods to identify inhibitors 182
- computational methods 182, 183
- fission yeast-based HTS 183, 184
- potency and selectivity 91
- quinazolinodione-related inhibitors of 182
- recent advancement in discovery for CNS-related disorders 173
- creating inhibitors by ligand-based virtual screening methods 173–176
- furan-containing class of inhibitors 176
- isothiazolo- and isoxazopyrimidone-based 178
- oxo- and thioxoquinazoline derivatives 174
- repositioning inhibitors designed for treatment of peripheral diseases 176–178
- recent advancement in discovery of dual inhibitors 178
- dual PDE4/7 inhibitors 178–180
- dual PDE7/8 inhibitors 180
- recent advances in discovery, for peripheral therapeutic benefit 169
- airway-related disorders 170
- nonairway-related disorders 171
- T cell-related disorders 169, 170, 171
- subtypes and distribution 165, 166
- target for treatment of airway 169
- targeting PDE4/7 dual inhibitors 168, 169
- as therapeutic agents for immunological diseases 171
- as therapeutic target, rationale for 166
- for treatment of neuropathic pain 172, 173
- potency and selectivity profile for spiroquinazolinone series 173
- spiroquinazolinone PDE7 inhibitors 172
- PDE8 inhibitors 6
- PDE8A
- affinity for cAMP 142, 143
- catalytic domain 142
- high affinity for cAMP 142
- human, homology of catalytic domain and binding motifs 142
- levels of expression 143
- potency and selectivity 85
- tissue distribution 143
- PDE8B 141
- C-terminal catalytic domain 142
- functions of 143
- adrenal gland 144
- pancreatic islets 144, 145
- thyroid 144
- high affinity for cAMP 142, 143
- inhibitors 145–150
- analogs lacking a fused ring 147
- structure–activity relationships 146
- tetrahydroisoquinoline scaffold 146, 147
- tetrahydropyranyl (THP) and tetrahydrofuran (THF) analogs 149
- *trans*-5-substituted nipecotate analogs 147
- levels of expression 143
- N-terminal REC domain 142
- PAS domain 142
- potential therapeutic uses 145–150
- tissue distribution 143
- substrate preferences 2
- PDE9 inhibitors 7, 105
- affinity of PDE9 inhibitors 111, 112
- clinical trials, for treatment of cognitive disorders 7
- dimer subtle asymmetry, in crystals 105–108
- conformational changes 107
- dimer of PDE9 catalytic domain 106
- hydrophobic interactions 105
- PDE9–Bay73-6691 complexes 107
- sequence alignment, of interfacial region 106
- implication on inhibitor selectivity 110, 113, 114
- interaction of inhibitors with 108, 109
- superposition of PDE9–(*R*)-Bay73-6691 over 109
- PDE9A inhibitors
- analysis of CNS desirability 135
- binding of 109
- and cerebrospinal fluid (CSF) cGMP levels 118
- CNS MPO (DO\_Desirability) score for 136
- crystal structures 119, 120
- efficacy, *in vivo* pharmacological behavioral models 118
- PF-4447943, clinical trials 118, 135
- treating cognitive disorders, medicinal chemistry efforts 118, 120
- Bayer 120–125
- Boehringer Ingelheim 129–132
- Envivo Pharmaceuticals 133, 134
- Pfizer 125–129
- Sun Yat-Sen University 132, 133

- selective 105
- PDE10 inhibitors 6
- papaverine-related PDE10A inhibitors 69–72
- patented papaverine-like PDE10A inhibitors 71
- pharmacophore model 70
- *in vivo* analysis of PQ-10 70
- x-ray cocrystallographic information 69
- phosphodiesterase 10A (PDE10A) inhibitors 65
- adverse events, reported 67
- cAMP binding to catalytic site of PDE10A 70
- catalytic domain bound with AMP 68
- company's Phase I and II studies 79
- crystal structure, of catalytic domain 67
- early PDE10A tool compounds 69
- enzyme kinetics, of PDE10A protein 66, 67
- enzyme structural difference, of splice variants 66
- glutamine in dual-substrate PDEs, rotation 67
- PDE10A protein expression in 65
- role in managing daily circadian rhythms 65
- structure-based design, role in understanding 68, 69
- therapeutic potential 65
- for treating central nervous system (CNS) disorders 65
- treatment of schizophrenia and Huntington's disease 7
- triazoloquinazoline PDE10 inhibitors 75
- PDE11 inhibitors 6, 10, 17, 32, 66, 163
- PET ligand development 77–79
- papaverine/quinazoline series 78
- PF-2545920/papaverine/quinazoline hybrid series of inhibitors 75–77
- pharmacophore model
- dimethoxy catechol-type PDE10A inhibitors 69, 70
- generated from lead PDE10A inhibitors 71
- libraries conceived using SNAr heteroaryl displacements by 70
- phenylalanine 32, 39, 110, 114, 204
- phosphorylation 30, 32, 37, 66, 156
- Plasmodium falciparum* 7, 191
- PfPDE $\alpha$  192, 193
- PfPDE $\beta$  192, 193
- phosphodiesterases 192–193
- conserved in nature 193
- tadalafil chemotype, for improved potency against cultures of 194
- p*-methoxybenzaldehyde 93
- polypharmacology 46, 58, 59
- positron emission tomography (PET) imaging 91, 92
- for biodistribution, of compounds 92
- prostatic hypertrophy, benign 2
- protein–ligand interaction 74
- protozoan PDEs. *see* human African trypanosomiasis; leishmaniasis; *Plasmodium falciparum*
- pulmonary arterial hypertension (PAH) 9
- sildenafil 9
- tadalafil 9
- pulmonary hypertension 2
- purin-6-one compounds 86
- pyrazolopyrimidines 12–18, 97, 98
- acidic chemotypes 17, 18
- basic, neutral, and acidic templates tested 17, 18
- C-3 structure–activity relationship (SAR) 17, 18
- 2D similarity with sildenafil 14
- high-throughput screening (HTS) 14, 15
- hydrophobic interactions 16
- N-1 alkylation 16
- non-P450 metabolism 17
- PDE potency and selectivity 158
- permeability issues 17
- Phase 2 trials 13
- physicochemical properties 15
- pyrazolopyrimidinones 162, 176
- pyrimidine-based templates amenable to parallel chemistry 15
- template follow-up clinical candidates 13
- UK-343664 13, 14
- UK-371800 13, 14
- x-ray crystallography 16
- pyridopyrazinones 18–24
- acidic nature 24
- CP-189824 18, 19
- designed 2-quinolone analog 20
- design options and associated synthetic strategy 22
- design strategies 21
- dihydropyrazinone intermediate 21
- effects of nitrogen positioning 23
- HTS screening 19
- identification of clinical candidate 23
- iminyl structure 21
- *n*-butyl group 19
- nitrogen insertion in core 23
- PF-489791 21, 24

- polar, nonreactive templates 21
- 2-quinolone template 19
- 4-quinolone to 2-quinolone transposition hypothesis 20
- superimposition of cocrystal structures for 4-quinolone HTS hit 20
- template oxidation confirmed with TosMIC 21
- use of hydroxyethylpiperidine 24
- pyridotriazine derivatives 89
- pyrimidine derivatives as tools, to probe inhibition of T-cell proliferation 169
- pyrimidinones 119, 120–123, 124, 125, 127, 128, 133, 135

## q

- quinazolinediones 145
  - based dual PDE7/8 inhibitors 186
  - derivatives displayed both PDE7 and PDE8 inhibition 180
  - related inhibitors of PDE7 182
- quinazoline inhibitors 75, 159, 160
  - derivatives, claimed as inhibitors 88–92
  - docked within PDE1 binding site, computer generated model 161
  - human PDE inhibition by 162, 163
  - x-ray structure 160

## r

- roflumilast 1, 29, 38, 46, 48, 55, 59, 202–204
- rolipram 29, 34, 39, 47, 52, 165, 174, 195, 202–204
  - analogs 55
  - insensitive cAMP-PDE type enzyme 165

## s

- SAR. *see* structure-activity relationship (SAR)
- schizophrenia
  - development of subtype-selective PDE9A inhibitors for 117
  - DISC1 gene disruption 38
  - MP-10/PF-2545920 class of inhibitors 72
  - MP-10/PF-2545920, clinical testing for 72
  - PDE5 as a mechanism and alternative indications beyond MED 11
  - PDE10 inhibitors in various phases of clinical development for 7
- signal transduction cascades 1
- sildenafil (Viagra®) 1, 2, 10
  - analogs 1
  - annual sales 9
  - commercialization 7

- drug design, and pharmacokinetic profiles
  - suitable for chronic dosing conditions 10
  - 2D similarity with 14
  - first-in-class agent for MED 10
  - IC<sub>50</sub> values 157
  - improved PDE1 potency 156
  - related structures 11
  - structure 10
  - template follow-up clinical candidates 13
  - template franchise 10
- sleeping sickness 191
- Sonogashira coupling 93
- spiroquinazoline 173, 176
- $\pi$ -stacking 95, 120, 126, 128, 133, 198
- structural features, of catalytic site 31, 32
- structure-activity relationship (SAR) 17, 51, 56, 57, 72, 73, 75, 87, 121, 130, 146, 172, 194, 202
- structure-aided drug design 7
- substrate preferences, for PDE 1, 2
  - cAMP-specific 2
  - cGMP-specific 2
  - mixed 2
- Suzuki reaction 20–22

## t

- tadalafil (Cialis®/Adcirca®) 1, 2, 10
  - analogs with antitrypanosomal activity 205
  - approval for the treatment of pulmonary arterial hypertension 9
  - chemotype, for improved potency against 197
  - less active against PDE6 and 10
  - PDE11 selectivity 10
  - peak sales 4
  - SAR study 194, 202
  - structure 10
- T cells 165, 169, 171, 184
- tetrahydronaphthyridines 146
  - microsomal oxidation 146
- thiadiazole 130, 168, 175, 176
  - 5-imino-1,2,4-thiadiazole derivatives 1755
- thienopyrazole derivatives 171
- triazolophthalazines 85, 86
- 6,7,8-trimethoxy-4-chloroquinazoline 161
- Trypanosoma brucei* 191
- Trypanosoma cruzi* 7, 191, 195

## u

- udenafil (Zydene®) 1, 5, 11, 12, 25

**ν**

van der Waals interaction 120

vardeafil (Levitra<sup>®</sup>/Staxyn<sup>®</sup>/Vianza<sup>®</sup>) 1, 4,  
9–11, 25, 156, 157

**x**

x-ray crystallography, 15, 24, 71, 74, 83, 97, 119,  
130, 160, 162, 197

**γ**

YM-393059 168, 178

– inhibiting proinflammatory cytokines  
169

**z**

zaprinast 156, 157, 193–195, 199, 202, 204